Is Axsome Therapeutics (AXSM) Undervalued As Revenue Run Rate Tops $1b?

Axsome Therapeutics (AXSM) has moved back into focus after reporting third quarter 2026 results that showed higher revenue and a smaller net loss, alongside an annualized revenue run rate above US$1b.

The earnings release helped spark a sharp rebound in Axsome Therapeutics, with a 1-day share price return of 5.87% and a 7-day share price return of 14.98%, even though the 90-day share price return is still down 30.15%. That mix of short-term momentum and a 5-year total shareholder return of 319.33% indicates that investors are reacting to the revenue run rate and pipeline updates as a fresh data point in a longer, still volatile story.

Scan Axsome Therapeutics alongside a curated group of CNS and healthcare specialists by checking out the 37 healthcare AI stocks that screen for similar themes in treatments and tech enabled drug development.

Axsome Therapeutics now trades with fresh enthusiasm after the earnings bounce, with the 90 day decline still in view. How much of that move reflects business progress rather than a swing in mood around the stock?

Most Popular Narrative: 45% Undervalued

On the analyst consensus Narrative on Simply Wall St, Axsome Therapeutics screens as materially undervalued, with a fair value of $271.05 against a last close of $149.24. That gap rests on a long runway of CNS products and an aggressive earnings ramp laid out in the model.

The company is advancing multiple late-stage clinical programs (AXS-05, AXS-12, AXS-14, and several solriamfetol indications), which positions Axsome to benefit from the aging population and rising prevalence of CNS disorders, potentially resulting in a diversified revenue base, higher earnings, and reduced risk of overreliance on a single product.

See why 41 investors see Axsome Therapeutics as 45% undervalued.

Result: Fair Value of $271.05 (UNDERVALUED)

Still, Axsome Therapeutics faces several significant pressures, including reliance on Auvelity and Sunosi for most sales, as well as ongoing net losses alongside heavy R&D and commercial spending.

Find out about the key risks to this Axsome Therapeutics narrative.

Next Steps

That mix of optimism and open questions only matters if you test it against the numbers yourself and move quickly to form your own view. Start by weighing the potential upside and risks through the 3 key rewards.

Looking for more Axsome Therapeutics style investment ideas?

If Axsome Therapeutics has caught your attention, do not stop here. Broaden your watchlist now and give yourself more options when the market shifts.

• Target potential mispricings by scanning a curated 32 high quality undervalued stocks that lines up strong fundamentals with prices that may not fully reflect their underlying business strength.
• Prioritize resilience by checking a focused 30 resilient stocks with low risk scores that filters for companies with steadier financial profiles and fewer red flags on key risk checks.
• Get ahead of the crowd by reviewing a hand picked 19 high quality undiscovered gems that combines solid financial quality with limited current market attention.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com